Skip to content

Effects of Catheter Ablation on Burden of Atrial Fibrillation (MRICEMAN)

A Nationwide Multicenter Trial Assessing the Effects of Catheter Ablation on Burden of Atrial Fibrillation Recorded by Implantable Cardiac Monitor

Status
UNKNOWN
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02639793
Acronym
MRICEMAN
Enrollment
300
Registered
2015-12-24
Start date
2016-01-31
Completion date
2020-01-31
Last updated
2015-12-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atrial Fibrillation

Keywords

arrhythmias, quality of life

Brief summary

The study will assess the atrial fibrillation burden recorded By implantable loop recorder at 12 and 24 months compared to baseline. The patients with clinical indication fo catheter ablation of paroxysmal atrial fibrillation will be randomized to three techniques: manual radiofrequency ablation, radiofrequency ablation using remote magnet monitoring, and cryoablation.

Detailed description

A total of 300 patients will be randomized to three different catheter ablation techniques (100 patients/group); radiofrequency ablation using remote magnet navigation, radiofrequency ablation using manual method, and cryoablation. A loop recorder (REVEAL) is implanted one month before the catheter ablation of paroxysmal atrial fibrillation and the effects of atrial fibrillation burden will be compared between the three methods at 12 and 24 months after ablation excluding the first three months´ blanking period. The primary endpoints are: 1. the proportion of patients remaining free from atrial fibrillation, atrial flutter or atrial tachycardia (\> 2 minutes) recorded by the implantable cardiac monitor (Medtronic) at 24 months follow-up and 2. total atrial fibrillation burden recorded by the loop recorder. Other endpoints: 1. Atrial fibrillation burden in 7 days Holter recording at 12 and 24 months compared to baseline, 2. the time to first documented symptomatic and asymptomatic recurrence of atrial fibrillation 3. prescription of antiarrhythmic drugs after the 3 months blanking period following the ablation 4. re-ablation after the index ablation procedure, 5. total procedural duration; 6. total time of fluoroscopy and radiation dose; 7. number and duration of cardiovascular hospitalization; 8. quality of life questionnaires at 12 months and 24 month compared with baseline, 9. cognitive function at 12 and 24 month compared with baseline, 10. cost-efficacy of the different ablation techniques.

Interventions

PROCEDUREcatheter ablation

Three different catheter ablation techniques will be used aimed at isolating the pulmonary veins from left atrium.The endpoint is defined as absence or dissociation of all pulmonary vein potentials as confirmed by the circular mapping catheter after a waiting period of 30 minutes after the last ablation. The use of adenosine or isoproterenol to detect concealed pulmonary vein conduction is voluntary.

Sponsors

University of Helsinki
CollaboratorOTHER
Heikki Huikuri
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No

Inclusion criteria

* Patients with symptomatic paroxysmal atrial fibrillation fulfilling the contemporary guideline criteria for AF ablation

Exclusion criteria

\- Any contraindication to catheter ablation

Design outcomes

Primary

MeasureTime frameDescription
Free of atrial fibrillation24 monthsthe proportion of patients remaining free from AF, atrial flutter (AFL) or atrial tachycardia (AT) (\> 2 minutes) recorded by the implantable cardiac monitor (ICM, Reveal, Medtronic Co.) at 24 months.

Secondary

MeasureTime frameDescription
Total AF burden24 monthstotal AF burden recorded by the implantable loop recorder during the 24 month follow-up.
Incidence of adverse events24 monthsSafety is one of the secondary endpoints. The following potential adverse events will be monitored: Any previous left atrial ablation or surgery Any cardiac surgery or percutaneous coronary intervention within three months prior to enrolment. Secondary AF Stroke or transient ischemic attack within six months prior to enrolment Myocardial infarction within three months prior to enrolment Left ventricular ejection fraction \< 40 % Anteroposterior left atrial diameter \>55 mm by transthoracic or transesophageal echocardiography Implanted prosthetic valve

Countries

Finland

Contacts

Primary ContactHeikki Huikuri, Prof
heikki.huikuri@oulu.fi+358400892330
Backup ContactPekka Raatikainen, Prof
pekka-raatikainen@hus.fi+35883154108

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026